Anavex Life Sciences (AVXL) Reports Q1 Loss of $0.12/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Anavex Reports Fiscal First Quarter 2016 Financial Results
February 8, 2016 7:00 AM ESTNEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimers disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months ended December 31, 2015.
Financial Highlights:
Anavex had cash and cash equivalents of approximately $13.8 million as of December 31, 2015, compared to approximately $15.3 million as at September 30, 2015.Anavex used approximately $1.5 million in net cash during the first three... MoreIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Ongoing Investigation of Anavex Life Sciences Corp. and Urges Investors with Losses in Excess of $250,000 to Contact the Firm
February 5, 2016 7:01 PM ESTLOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC announces it is investigating claims against Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL) concerning... More
